Peloton planning Phase III kidney cancer study with $150M series E

With the proceeds of its new $150 million series E round, Peloton Therapeutics Inc. (Dallas, Texas) plans to start a Phase III trial next half of lead candidate PT2977 to treat

Read the full 316 word article

How to gain access

Continue reading with a
two-week free trial.